Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

Published:2023-06-05 Issue:1 Volume:24 Page:
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Xiao Lanshu¹²,Liu Yi¹,Chen Hui¹^ORCID,Shen Lisong¹²³^ORCID

Affiliation:

1. Department of Clinical Laboratory, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2. Faculty of Medical Laboratory Science, College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

3. Institute of Artificial Intelligence Medicine, Shanghai Academy of Experimental Medicine, Shanghai, China

Funder

National Natural Science Foundation of China

Lisong Shen, Hui Chen, and Yi Liu, the Shanghai Key Clinical Specialty Construction Project

Lisong Shen, and the Shanghai Sailing Program

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2023.2219470

Reference142 articles.

1. The ever‐increasing importance of cancer as a leading cause of premature death worldwide

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Prodrugs for targeted cancer therapy

4. CDK9: a signaling hub for transcriptional control

5. Structural insights into the functional diversity of the CDK–cyclin family

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK9 inhibitors for the treatment of solid tumors;Biochemical Pharmacology;2024-11

2. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma;Biochemical Pharmacology;2024-08

3. CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer;Biomedicine & Pharmacotherapy;2024-08

4. CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma;Clinical Cancer Research;2024-07-25

5. Single-molecule live imaging of subunit interactions and exchange within cellular regulatory complexes;2024-06-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3